Episode 67
Biotech Hangout
00:00
The Bioplausibility of Reata's Oxalone
I don't follow this company at all. I saw a couple tweets about potential safety issues or something. Can you just describe that more in depth? Then is there any chance that this blows up in biogen's face? But what like tell us more about that? Oh, man. So we'd have to we'd probably have to Schedule a separate like 10 hour, um, hang out to really discuss all the history of reata and the uh, NRF 2 assets,. The short story here is they had another asset that which there was a safety issue a number of years ago That asset the the chemistry there are their analogs for an oxalone.
Transcript
Play full episode
